ORKA
What one share of Oruka Therapeutics holds
Pharmaceutical Preparations
Closing”), we completed our acquisition (the “Merger”) of Oruka Therapeutics, Inc. (“Pre-Merger Oruka”) pursuant to an Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024 (the “Merger Agreement”). Following the transactions contemplated by the Merger Agreement, Pre-Merger Oruka merged with and into Atlas Merger Sub Corp., a wholly owned subsidiary of ARCA biopharma, Inc.
Oruka Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.87 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.42 |
| Cash and investments | $18.43 |
| Book value | $18.25 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2015 | $0.00 | −$1.82 | $0.00 | −$1.68 | — | $4.21 |
| 2016 | $0.00 | −$1.81 | $0.00 | −$1.65 | — | $2.44 |
| 2017 | $0.00 | −$1.77 | $0.00 | −$1.68 | — | $0.87 |
| 2018 | $0.00 | −$10.31 | $0.01 | −$10.72 | — | $7.80 |
| 2019 | $0.00 | −$4.15 | $0.00 | −$3.64 | — | $4.77 |
| 2020 | $0.00 | −$2.07 | $0.00 | −$1.64 | — | — |
| 2021 | $0.00 | −$1.39 | $0.00 | −$1.35 | — | $3.54 |
| 2022 | $0.00 | −$0.69 | $0.00 | −$0.76 | — | $2.89 |
| 2023 | $0.00 | −$0.37 | $0.00 | −$0.35 | — | $2.55 |
| 2025 | — | −$1.85 | $0.00 | −$1.55 | — | $9.69 |